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Background: Studies on the inherited bleeding disorder, Glanzmann thrombas-
thenia (GT), have helped define the role of the aIIbb3 integrin in platelet aggre-
gation. Stable bent aIIbb3 undergoes conformation changes on activation
allowing fibrinogen binding and its taking an extended form. The aIIb genu
assures the fulcrum of the bent state. Our goal was to determine how structural
changes induced by missense mutations in the aIIb genu define GT phenotype.
Methods: Sanger sequencing of ITGA2B and ITGB3 in the index case followed by
in silico modeling of all known GT-causing missense mutations extending from the
lower part of the b-propeller, and through the thigh and upper calf-1 domains.
Results: A homozygous c.1772A>C transversion in exon 18 of ITGA2B coding
for a p.Asp591Ala substitution in an interconnecting loop of the lower thigh
domain of aIIb in a patient with platelets lacking aIIbb3 led us to extend our in
silico modeling to all 16 published disease-causing missense variants potentially
affecting the aIIb genu. Modifications of structuring H-bonding were the major
cause in the thigh domain although one mutation gave mRNA decay. In contrast,
short-range changes induced in calf-1 appeared minor suggesting long-range
effects. All result in severe to total loss of aIIbb3 in platelets. The absence of
mutations within a key Ca2+-binding loop in the genu led us to scan public data-
bases; three potential single allele variants giving major structural changes were
identified suggesting that this key region is not protected from genetic variation.
Conclusions: It appears that the aIIb genu is the object of stringent quality con-
trol to prevent platelets from circulating with activated and extended integrin.
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1 | INTRODUCTION
Integrins are cell membrane proteins composed of a series
of a- and b-subunits that noncovalently associate into 24
ab heterodimers with divalent cation-dependent adhesive
functions (Horton et al., 2015; Hynes, 2002). aIIbb3 medi-
ates platelet aggregation by binding fibrinogen (Fg) or
other adhesive proteins; in contrast, the closely related
avb3 is more generally expressed and has wider functional
diversity (Coller & Shattil, 2008; Ley, Rivera-Nieves,
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Sandborn, & Shattil, 2016). av and aIIb have 4 major
extracellular domains (b-propeller, thigh, calf-1 and calf-2)
while b3 has 8 (bI, hybrid, PSI (plexin/semaphorin/inte-
grin), 4 EGF (epidermal growth factor) domains and the b-
tail). The NH2-terminal b-propeller of aIIb (or av) and the
bI (sometimes called bA) domain of b3 associate to form a
ligand-binding globular headpiece; biochemical and bio-
physical studies all show that the heads are attached to legs
(or stalks) with single pass transmembrane sequences and
cytoplasmic tails distinctive of each subunit (Adair & Yea-
ger, 2002; Carrell, Fitzgerald, Steiner, Erickson, & Phillips,
1985; Xiao, Takagi, Coller, Wang, & Springer, 2004;
Xiong et al., 2001, 2009; Ye et al., 2010; Zhu et al.,
2008).
Although different biophysical approaches have given
varying interpretations of subunit domain arrangements,
crystal structures show avb3 and aIIbb3 extracellular
domains with a bent conformation in their resting state
with the closed head pointing downwards toward the mem-
brane (Takagi, Petre, Walz, & Springer, 2002; Zhu et al.,
2008). The major bend occurs at the aIIb genu situated
between the thigh and calf-1 domains and the “knee” of b3
where a link between I-EGF-1 and I-EGF-2 is at the epi-
center of conformational change. Recent studies from Col-
ler and his coworkers using purified aIIbb3 in a nanodisc
bilayer also suggest a bend involving aIIb calf-1 and calf-2
domains and an involvement of b3 I-EGF-2-4 domains
(Choi, Rice, Stokes, & Coller, 2013; Coller, 2015).
Notwithstanding the model, aIIbb3 structure is flexible and
multiple conformational changes in response to activation
lead to opening of the head and, for the majority of
authors, a “switchblade” straightening of the extracellular
domain (Choi et al., 2013; Coller, 2015; Li et al., 2017;
Xiao et al., 2004; Zhang & Chen, 2012; Zhu, Zhu, &
Springer, 2013; Zhu et al., 2008). This permits high affin-
ity ligand binding and facilitates adhesive functions. While
much is known of the structure of the aIIbb3 headpiece,
less is known about the molecular interactions at the ful-
crum where the legs bend in the resting integrin (Blue
et al., 2010; Smagghe, Huang, Ban, Baker, & Springer,
2010; Xiong et al., 2009).
Glanzmann thrombasthenia (GT, MIM #273800) is an
autosomal recessive inherited platelet disorder characterized
by excessive bleeding and quantitative or qualitative defi-
ciencies of aIIbb3 (George, Caen, & Nurden, 1990). As a
result, platelets do not bind Fg and fail to form the bridges
which crosslink them in an aggregate. Molecular screening
of ITGA2B (MIM #607759) and ITGB3 (MIM #173470),
the genes that encode for aIIb and b3, has identified many
genetic causes of GT (splice variants, insertions, deletions,
nonsense, and missense mutations) (Buitrago et al., 2015;
Nurden, Fiore, Nurden, & Pillois, 2011; Nurden & Pillois,
2017; Nurden et al., 2015). Mostly these cause a lack (type
I GT) or much reduced aIIbb3 expression (type II GT),
although occasional qualitative variant forms have provided
much information on how aIIbb3 functions (reviewed in
Coller & Shattil, 2008; Nurden et al., 2011). Significantly,
a systematic analysis of ITGA2B and ITGB3 variants iden-
tified in 16,108 individuals by new generation sequencing
technologies has shown heterozygous expression of mis-
sense variants to be quite widespread in the normal popula-
tion (Buitrago et al., 2015). Despite recent advances,
questions of how critical is the genu for integrin expression
and function remain largely unanswered. Our finding of a
novel missense mutation in the genu region of aIIb in a
Belgium patient with type I GT led us to review other, nat-
ural or engineered, published variants localized within
amino acids (aa) 471-769 incorporating the thigh and the
upper calf-1 domain of aIIb by using in silico modeling to
look at their potential structural impact.
2 | CASE HISTORY AND METHODS
2.1 | Patients
2.1.1 | Index case
The index case is an adult Caucasian woman of Belgian
nationality with type I GT whose platelets fail to aggregate
with physiologic agonists (Wertz, Boveroux, Peters,
Lenelle, & Franssen, 2011). She had a severe bleeding
diathesis that included several episodes of gastric hemor-
rhage that twice resulted in hospital treatment. She devel-
oped antibodies to aIIbb3 after platelet transfusions and
was operated for spheno-orbital meningioma under the
cover of recombinant Factor VIIa. Some 8 days later she
developed internal jugular venous thrombosis probably
linked to catheter use (Wertz et al., 2011). Standard flow
cytometry confirmed the lack of aIIbb3 on her platelets but
trace amounts of b3 suggested that avb3 was conserved.
DNA was extracted with the QIamp DNA Blood Mini kit
(Qiagen, Courtaboeuf, France) from EDTA-anticoagulated
whole blood. Sanger sequencing of exons, splice sites and
untranslated regions of the ITGA2B and ITGB3 genes was
performed according to our published procedures (Nurden
et al., 2015). This study was performed in accordance with
the declaration of Helsinki after written informed consent
from the patient, and under the approved ethical guidelines
from the French National Institute for Medical Research
(INSERM; approval RBM-04-14).
2.1.2 | Other cases
We performed a literature research for missense variants
affecting amino acids 471-769 extending from the base of
the b-propeller, through the thigh to the upper calf-1
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domain of human aIIb using PUBMED (https://www.ncbi.
nlm.nih.gov/pubmed) (Keywords: Glanzmann thrombasthe-
nia). Clinical and biological data were obtained retrospec-
tively from the cited publications and are summarized and
referenced in Table S1. For a wider view we also
researched missense variants from the Human Genome
Mutation Database, the 1000 Genomes project, the United
Kingdom 10K Whole Exome Sequencing project, and the
National Heart, Lung and Blood Institute Exome Sequenc-
ing Project as assembled by Buitrago et al. (2015) and
updated the information within control populations by
searching ExAC (www.exac.broadinstitute.org) and
Ensembl genome browsers (www.ensembl.org; Herrero
et al., 2016) according to Institutional Review board
guidelines.
2.1.3 | Nucleotide and amino acid numbering
Human Genome Variation Society (HGVS) nomenclature
for cDNA and protein is used throughout unless stated
otherwise. For nucleotide numbering, the A nucleotide of
the ATG start codon was designated +1 (cDNA ITGA2B
Genbank accession number NM_000419.3). For amino acid
numbering, +1 starts with the initiating Met with signal
peptide included. This is often followed by that of the
mature protein (in parentheses), this involves subtracting
31 amino acids from the HGVS numbering of aIIb and 26
for b3. Amino acid numbering for the mature protein was
previously used in the crystal structure of aIIbb3 and sub-
sequent in silico modeling (see Xiao et al., 2004; Zhu
et al., 2013). Alamut Visual software version 2.9 (Interac-
tive Biosoftware, Rouen, France) was the primary source
(1) for evaluation of nucleotide and amino acid conserva-
tion between species and within other integrin a subunits,
(2) for estimating the physical-chemical difference between
amino acids (Grantham score) and (3) for the pathogenicity
of the newly substituted amino acid by SIFT (version 6.2),
PolyPhen and Mutation Taster (Nurden et al., 2015).
2.1.4 | In silico modeling
Protein models were constructed using the PyMol Molecu-
lar Graphics System, version 1.3, Schr€odinger, LLC (www.
pymol.org) and 3fcs or 1uv9 pdb files for crystal structures
of aIIbb3 as described by us (Nurden et al., 2011, 2015).
Amino acid changes are visualized in the rotamer form
showing side change orientations incorporated from the
Dunbrack Backbone library with the maximum probability.
Sequences composing the genu region are not continuous
and are defined by color codes in our molecular models
and framed in Figs S1 and S2 that show the conservation
of amino acid residues between species and other integrin
a-subunits.
3 | RESULTS
3.1 | A novel mutation affecting the aIIb
genu causing type I GT
Sanger sequencing of DNA from the index case, a Belgium
type I GT patient, identified a homozygous c.1772A>C
transversion (NC_000017.11:g.44379795T>G) affecting
exon 18 of ITGA2B. It is a rare allele, featuring in one report
on public databases, rs778608263 with a minor allele fre-
quency (MAF) G = 0.000008354 (ExAC). This variant
gives a p.Asp591Ala substitution (D560A for mature aIIb).
Asp591 is highly conserved within vertebrates and is
retained in all human integrin a-subunits (Figs S1 and S2).
The physical and chemical deviation between Asp and Ala is
large (Grantham score: 126) and the mutation is described as
“deleterious” by SIFT, “probably damaging” by PolyPhen
and “disease causing” by Mutation Taster (Alamut Visual).
aIIbD591 localizes to the lower part of the thigh directly
affecting the intermediate or linker sequence composing the
aIIb genu. As shown in Figure 1, the thigh domain is com-
posed of seven antiparallel b strands forming a b barrel; con-
necting loops contain several polar amino acids whose side
chains are involved in structuring H-bonds. Among them,
aIIbAsp591 shares H-bonds with at least three neighboring
amino acids (Arg551, Leu593 and Ser594). Its substitution
by Ala results in the loss of these structuring H-bonds (Fig-
ure 1a, inset). The fact that platelets from the patient lack
aIIbb3 indicates an early block in aIIbb3 biosynthesis.
3.2 | Distribution of known missense variants
in and around the aIIb genu
A comprehensive search of the literature revealed 15 mis-
sense variants causative of GT within the aa471-769
sequence that begins with the C-terminal strands of the b-
propeller, extends through the thigh domain and terminates
with the upper domain of calf-1 (Table S1) (Figures 1 and
2). All were associated with type I or type II GT and absent
or much-reduced levels of aIIbb3 in their platelets. Bleeding
severity differed widely between these patients and indepen-
dent of the site of the amino acid substitution. Two additional
low frequency human platelet alloantigen (HPA) systems,
Ser503Asn (HPA-24b) in the thigh domain and Thr650Met
(HPA-20b) in calf-1 fail to affect aIIbb3 expression and are
associated with a post-transfusion immune response but not
lack of function (Jallu, Dusseaux, & Kaplan, 2011; Peterson
et al., 2010). Interestingly, of the 15 GT-causing mutations
only Ile596Thr featured in the list released by Buitrago et al.
(2015) who analyzed nonsynonymous variants affecting
ITGA2B and ITGB3 identified by whole exome and whole
genome human sequencing in over 16,000 normal individu-
als in the ThromboGenomics project. Nevertheless 16 (thigh)
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FIGURE 1 Ribbon diagrams highlighting selected missense mutations in and around the genu region of aIIb. The lower left panel shows a cartoon
representation of the entire extracellular domain of aIIb with the genu in dark blue. Missense mutations most closely affecting this region are in red and
numbered from 1 to 7. Framed are groups of missense variants within (a) connecting loops from the base of the thigh domain; (b) the unstructured linker
ribbon between the thigh and the calf-1 domains that contains a Ca2+ loop; and (c) the lower bend of the genu which contains a H-bond clasp. In small
windows are enlarged views of mutations illustrated as graphical sticks with superimposed the natural amino acid represented as lines. Graphical “bumps”
(red discs) reveal steric encumbrance caused by the amino acid substitution. Amino acids engaged in H-bonds (dotted lines) are represented as sticks with
C atoms in white, N atoms in blue, O atoms in red and S atoms in orange. In (a) the black arrow indicates the position of Ile596; for Ile596Thr numbers in
red are interatom distances in Angstroms, while a red dotted line represents a potential H-bond introduced by the presence of Thr596. In (b) the Ca2+ is
represented as a gray sphere and the dotted lines coordination links to nearby amino acids. Models were obtained using the PyMol Molecular Graphics
System, version 1.3 and the 3fcs pdb file
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and 23 (calf-1) nonsynonymous missense variants of
unknown pathogenicity were present. A current assessment
of the aa471-769 sequence in the ExAC database (ITGA2B,
21/08/2017) revealed 97 missense variants. This increased to
134 when Ensembl was consulted; a list that now includes
presumed heterozygous expression of eight of the 15 variants
causative of GT when homozygous or part of compound
heterozygosity. Clearly, the genu and surrounding regions of
aIIb are undergoing constant evolutionary genetic change.
3.3 | Structural consequences of missense
variants within the thigh and its connecting
loops
To better understand the pathological influence of the
Asp591Ala variant we first performed in silico modeling of
domains close to and including the upper connecting loops
of the genu.
• C-terminal domain of the b-propeller. The only known
disease-causing b-propeller mutation in our selected
aa471-769 sequence is a homozygous Ala477Pro
(A446P) substitution in a Chinese boy with type II GT
(Fu, Yuan, Chen, Xia, & Fu, 2005). Ala477 lies in the
middle of the 3rd b-strand of the seventh blade of the b-
propeller close to the link to the thigh domain (Fig. S3).
This blade is clearly critical as it closes the circular pro-
peller by interacting with blade 1; introduction of a Pro
with its tendency to form a b-turn into the center of a b-
sheet creates a tension that weakens H-bonds that link
the third and fourth b-strands of blade 7 together. Site-
directed mutagenesis in CHO cells by Fu et al. (2005)
FIGURE 2 Cartoon representations of selected missense mutations within the aIIb calf-1 domain. On the left hand side is a ribbon diagram
depicting the extracellular domains of aIIb with the genu region colored in dark blue. Framed is the calf-1 domain with missense mutations
colored in red and numbered from 1 to 5. On the right hand side are selected representations of the calf-1 domain with selected mutations as red
sticks. The calf-1 domain is structured as a b-barrel composed of multiple anti-parallel b-strands. Amino acids whose side chain point to the core
of the barrel are colored in gray and represented as spheres in the far right representations. In the small windows are enlarged views with each
mutation illustrated as graphical sticks with superimposed, the natural amino acid represented as lines. C atoms are colored in white, N atoms in
blue, O atoms in red and S atoms in orange. Graphical “bumps” (red discs) reveal steric encumbrance caused by the amino acid substitution.
Models were obtained using the PyMol Molecular Graphics System, version 1.3 and the 3fcs and 1uv9 pdb files
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showed that surface expression of aIIbPro477b3 was
reduced to 14% of wild-type levels. Western blotting
showed pro-aIIb to be synthesized and immunofluores-
cence labeling revealed that the mutated pro-aIIbb3 was
retained in the ER. Interestingly, a near-neighbor
homozygous Ile458Met mutation in an Indian boy gave
type I GT (Vijapurkar, Ghosh, & Shetty, 2009).
• Disease-causing thigh and linker-domain mutations. One
of the H-bonds of Asp591 (mutated in the index case
above) is with Arg551 of aIIb (Figure 1a); Arg551
(R520) is a mutation hotspot for GT with homozygous
substitution by Trp in two patients (cases 4 and 5) origi-
nating from Southern India (Nelson et al., 2006) or by
Gln in a young boy from India (case 6) and five patients
(cases 7–11) from three unrelated families in Pakistan
(Haghighi et al., 2016; Viyapurkar et al., 2009)
(Table S1). Both substitutions give type I GT and sub-
stantial bleeding. Arg551 is highly conserved both
between species and within human integrin a-subunits
(Figs S1 and S2) and like Asp591 it localizes to a con-
necting loop of the lower region of the thigh domain. In
fact, both substitutions of Arg551 lead to the loss of
multiple structuring H-bonds, with the larger Trp addi-
tionally introducing steric encumbrance (Figure 1a
insets).
• Close to Asp591, Ile596Thr (I565T) has been the object
of several reports mostly from Europe, giving rise to type
I GT with moderate to severe bleeding (Table S1). Two
cases have homozygous expression; in the other three,
Ile596Thr is part of compound heterozygosity paired
with IVS29(+2)T>C, c.3091delC or a well-characterized
Glu355Lys (E324K) missense mutation (French & Col-
ler, 1997; Jallu et al., 2010; Ruan et al., 1998; Sandrock
et al., 2012; Sandrock-Lang et al., 2015). Thus Ile596
(localized on Figure 1a) is a likely mutational hot spot.
Ile596 is relatively well conserved both between species
and within human a-subunits; when nonconserved the
replacement amino acids have similar biochemical prop-
erties and steric encumbrance (Figs S1 and S2). The
physical and chemical deviations between the amphi-
pathic C5 Ile and the polar uncharged C4 Thr are modest
(Grantham score: 89) and at first sight, in silico modeling
suggests the impact of the Thr substitution to be minor.
However, Thr introduces an -OH alcoholic function close
(3.4A) to Arg551, this competes for H-bonds with aIIb
residues Asp542, Ser594 and Asp591 changing interatom
distances and creating an additional H-bond within con-
necting loops extending from the lower region of the
thigh (Figure 1a).
A homozygous Pro507Arg (P476R) thigh domain substi-
tution was detected in a patient from India (Peretz et al.,
2006). Pro507 is poorly conserved (Figs S1 and S2) but
the physical and chemical deviation between Pro and Arg
is important (Grantham score: 103). Predicted to be dele-
terious by SIFT and possibly damaging by PolyPhen it is
defined as a polymorphism by Mutation Taster confirm-
ing the unpredictability of these programs as highlighted
elsewhere (Buitrago et al., 2015). As in silico modeling
performed by the authors localized Pro507 to the tip of a
loop and partially buried within the subunit, we have
concentrated our modeling in this zone to Ile518Asp
(I487D) and Ala581Asp (A550D). Ile518Asp (case 3,
Table S1) is part of compound heterozygosity with a
c.1946+3G>T splice site variant in a young American
male with type I GT and severe bleeding (Nurden et al.,
2015). It is predicted to be possibly damaging or deleteri-
ous. Ala581Asp (case 12, Table S1) also had heterozy-
gous expression being the only mutation found in an
Italian type I GT patient, suggesting a second nonidenti-
fied defect (D’Andrea et al., 2002). Like Pro507Arg,
Ile518 and Ala581 locate to the thigh b-barrel. Composed
of seven b-strands; the b-barrel is largely made up of
hydrophobic amino acids whose side chains point to the
core of the structure whereas side chains of polar or
charged amino acids point to the outside. Ile518 and
Ala581 are hydrophobic and the introduction of a highly
charged Asp in both cases introduces deep instability
(Fig. S4) with a block in aIIbb3 biosynthesis explaining
its absence from the platelet surface and type I GT.
• Ca2+-binding loop in the genu. A clearly defined struc-
ture of the aIIb genu is a Ca2+ loop with two Cys
(Cys633 and Cys639) involved in a disulfide bridge and
four amino acids engaging in Ca2+ coordination
(Cys633, Asp636, Val638, and Glu673) (Figure 1b). At
the present time, none of these amino acids are mutated
in a GT patient. However, on performing a database
search we found missense variants for 3 of them on the
Ensembl database: Cys633Ser (rs1126555; no frequency
data), Asp636Asn (rs749873100; MAF 0.00004) and
Glu673Lys (rs368974006; MAF 0.00002/8). Although
no biological or clinical information associated with
these mutations is available, at least Cys633Ser is stated
as being probably damaging by Polyphen, and our in sil-
ico modeling shows that Cys633Ser and Glu673Lys
have a deep impact on aIIb structure (Figure 1b): the
first by disrupting the disulfide bridge, and the second
by affecting Ca2+-binding. Thus structure-modifying
mutations directly affecting the aIIb genu are present
already in the normal population showing that this
region too is the object of evolutionary change.
• Nonsynonymous variants in the thigh domain associated
with mRNA loss. Homozygous Gln626His (Q595H) giv-
ing type I GT was independently detected in four Euro-
pean studies suggesting a possible founder effect (Jallu
et al., 2010; Nurden et al., 2015; Pillitteri, Pilgrimm, &
Kirchmaier, 2010; Sandrock et al., 2012). In fact, the
254 | PILLOIS ET AL.
c.1878G>C transversion responsible for Gln626His pri-
marily effects splicing with exon skipping leading to
mRNA decay (Jallu et al., 2010; Nurden et al., 2015).
In fact, when aIIbHis626b3 was co-expressed with b3
in COS-7 cells, surface expression of aIIbb3 was normal
(Jallu et al., 2010). In a parallel study, Kamata et al.
(2010) engineered Gln626 substitution by Asn, Ala,
Asp, and Trp among others and found that none of them
prevented expression of the recombinant integrin in
CHO cells; furthermore the mutated aIIbb3 remained
nonactivated and therefore bent. Because of the strategic
position of Gln626 we performed in silico modeling to
examine short-range changes introduced by these engi-
neered variants on integrin structure. Figure 1c shows
how Gln626 forms a H-bond with Asn722 in calf-1 and
together with near-neighbor Asp495 that forms a H-bond
with Ser759 in calf-1 constitutes a H-bond clasp. His626
and Asn626 introduce modest structural changes and
have little effect on H-bonding (Figure 1c). While sub-
stitution of Gln626 with the smaller Ala, the oppositely
charged Asp, or the bulky Trp cause loss or weakening
of at least one of the H-bonds, sufficient interaction is
retained so that the clasp is not broken. Our in silico
modeling therefore helps explain the retention of recom-
binant aIIbb3 expression after transfection in heterolo-
gous cells.
3.4 | Repertoire of variants in the calf-1
domain
Calf-1 has a b-structure with nine b-strands connected to
the NH2-terminus of the thigh domain through intercon-
necting loops. Our literature research identified nine dis-
ease-causing missense variants within the genu-proximal
part of calf-1 (Table S1). D’Andrea et al. (2002) reported
Arg755Pro (R724P) coexpressed with Leu752Val (L321V)
in a patient with type I GT; intriguingly both variants had
homozygous expression suggesting a rare haplotype. Sub-
sequently, homozygous Arg755Pro alone was found in a
young Indian woman with mild bleeding and type I GT
(Vijapurkar et al., 2009). While Arg755 is moderately con-
served within species or human a-subunits, Leu752Val is
only weakly conserved suggesting a low importance for
integrin biosynthesis and/or function (Figs S1 and S2). We
identified heterozygous Arg755Gln in two siblings from
the USA with type I GT and severe bleeding but very
unusually both siblings also expressed two potentially
heterozygous disease-causing ITGB3 mutations so the role
of Arg755Gln in the GT phenotype is difficult to predict
(cases 35a,b in Nurden et al., 2015). This is even more so
as aIIbArg755Pro, Arg755Gln, and Leu752Val are all
reported as tolerated by SIFT, probably or possibly damag-
ing by PolyPhen and disease causing by Mutation Taster,
again underlining the variability in the prediction algo-
rithms. The effects of Arg775Pro, Arg755Gln, and Leu752-
Val on the structure of calf-1 are first compared in
Figure 2. Arg755 localizes to the upper end of a b-strand
with its side chain aligning toward the exterior limiting the
short range structural effect within aIIb of its substitution
by Gln or Pro. Significantly, long-range effects were
recently identified for these substitutions from molecular
dynamics simulations (Goguet, Narwani, Petermann, Jallu,
& De Brevern, 2017). The jury is out on whether the rela-
tively inert Leu752Val contributes to the type I GT pheno-
type. At the interface between calf-1 and calf-2 Pro772Arg
(and erroneously stated to be within calf-2 in the original
report) was not considered further by us.
Other missense mutations affecting calf-1 concern resi-
dues that locate to b-strands central to the b-barrel (Fig-
ure 2) but few studies have investigated how they
influence aIIb structure. Thr646Ala (T615A) was detected
in a Turkish patient with type I GT (Tokgoz, Torun Ozkan,
Caliskan, & Akar, 2015). Thr646 points to the exterior and
its replacement by the smaller Ala on aIIbb3 structure is
difficult to predict. Leu684Arg (L653R) was found in a
type I patient from Italy but with heterozygous expression,
a presumed mutation affecting the second allele remains to
be identified (Pillitteri et al., 2010). Leu684Arg concerns
the hydrophobic core of the b-barrel replacing a hydropho-
bic amino acid with a larger polar residue introducing steric
encumbrance (red bumps on Figure 2), a change having a
highly destabilizing effect. Of much interest is Cys705Arg
(C674R) first detected as part of compound heterozygosity
in a Spanish patient with type II GT (Gonzalez-Manchon
et al., 1999). The second allele for this patient had a splice
site mutation, IVS5(+2)C>A that led to insertion of intron
5, mRNA instability, and a loss of aIIb. As is shown on
Figure 2, substitution of Cys705 results in loss of the
aIIbCys705-Cys718 disulfide bridge; this renders the b-bar-
rel unstable promoting expression of the hydrophobic core
at the exterior. The same variant was subsequently detected
in three Italian families with homozygous expression in
two of them and as part of nonidentified compound
heterozygosity in a third (D’Andrea et al., 2002). Mitchell
et al. (2003) independently identified homozygous
Cys705Arg in another Italian man with type II GT. The sit-
uation in the latter family was complicated as aIIbI-
le405Thr formed part of compound heterozygous
expression in other affected members (Mitchell et al.,
2003). Heterozygous Cys705Arg has since featured in two
later reports from France where it combined with intronic
splice defects on the second allele that cause loss of
expression (Jallu et al., 2010; Nurden et al., 2015). The
location of many patients with Cys705Arg in Europe
strongly suggests a founder defect. Finally, heterozygous
expression of Cys705Leu (C674L) in a German patient
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with <5% aIIbb3 has similar effects although for this
patient a second allele mutation remains to be found (San-
toro et al., 2010) (Figure 2). Interestingly, when aII-
b705Arg was transfected with wild-type b3 in CHO cells
formation of the pro-aIIbb3 complex still occurred (Gonza-
lez-Manchon et al., 1999). Although maturation and sur-
face expression of the mutated complex was greatly
disrupted there was sufficient expression to account for the
type II phenotype.
4 | DISCUSSION
Despite occurring in an a-priori critical region for changing
between resting and activated states, we show that disease-
causing variants within or near the aIIb genu are primarily
associated with defects of aIIbb3 maturation and a loss of
surface expression. The genu links the calf-1 and thigh
domains (see Introduction) of aIIb whose key features sug-
gested from the crystal structures of avb3 and aIIbb3
include (1) multiple b-sandwich folds, (2) intermediate
loops extending from the base of the thigh to the top of
calf-1 and (3) an a-b interface between the thigh and EGF-
domains (Xiong et al., 2001, 2009; Zhu et al., 2008). A
well-coordinated Ca2+ lies in an extended loop of the genu
close to calf-1 and may help neutralize opposing acidic
patches at the a-b subunit interface. Our finding of a novel
aIIb substitution (Asp591Ala) in a Belgian patient with
type I GT that concerned an amino acid localized within a
connecting loop of the lower region of the thigh domain
and influencing genu structure by participating in a highly
structured network of H-bonds highlights the potential
structural importance of this region. This led us to review
the effects of other natural amino acid substitutions within
an arbitrarily chosen amino acid 471-769 sequence extend-
ing down from the base of the b-propeller through the thigh
and the upper region of calf-1. Significantly, H-bond loss
was a frequent finding with the disease-causing mutations.
All 15 GT-causing missense variants previously identi-
fied within the amino acid 471-769 sequence resulted in
loss or severely reduced aIIbb3 expression in platelets
(Table S1); a result confirmed in certain studies after
expression of recombinant mutated integrin in heterologous
cells (Fu et al., 2005; Gonzalez-Manchon et al., 1999).
Such results mimic those obtained for a much larger num-
ber of missense mutations detected in the b-propeller head
of aIIb (Nelson et al., 2005, 2006; for a more recent
review see Nurden et al., 2011), but contrasts with the b1
(or bA) extracellular domain of b3 where classic
Asp145Asn/Tyr (D119N/Y), Arg240Gln/Trp (R214Q/W)
substitutions allow aIIbb3 expression but prevent formation
of a functional ligand-binding pocket (reviewed in Coller
& Shattil, 2008; Nurden et al., 2011). No Fg-binding
domains have been located to the aIIb genu or near-neigh-
bor domains, although heparin and heparin sulfate may
bind to integrins by way of Lys or Arg residues in this
region offering a potential for modifying integrin function
(Ballut, Sapay, Chautard, Imberty, & Ricard-Blum, 2013;
Yagi et al., 2012). Interacting platelets are sources of reac-
tive oxygen species (ROS) able to modulate aIIbb3 func-
tion by oxidizing cysteines as part of cellular redox
regulation (Essex, 2009). Studies on a7b1 suggest that a
primary site for ROS are Cys residues in the genu a find-
ing that also has functional implications (de Rezende et al.,
2012). Cytoplasmic domain missense mutations of aIIb
(e.g. Arg1026Gln or Trp; R995Q/W) or b3 (e.g. Leu744-
Pro or Ser778Pro (L718P or S752P) can have long-range
effects on the extracellular domains either by abrogating
“inside-out” signaling pathways dependent on talin and
kindlin-3 binding to the b3 cytoplasmic tail or conversely
lead to partially activated integrin and defects of platelet
production (reviewed by Nurden et al., 2011; Nurden &
Pillois, 2017). No platelet size variations were seen in our
selected GT cohort.
In silico modeling of the aIIb Asp591Ala mutation in
the index case showed a loss of close-range H-bonds
including Arg551, itself a mutation hotspot for GT being
substituted either by Trp or by Gln in several unrelated
type I patients (Table S1). Asp591 and Arg551 localize to
connecting loops between b-sheets forming the b-barrel
structure of the thigh domain, proximal to the genu. Steric
interference (particularly for Trp551) and a reduced posi-
tive charge weakened structured H-bonds involving side
chains of the mutated amino acids. H-bond modifications
were also induced by Ile596Thr another common mutation
giving type I GT. Here the introduction of Thr influenced
neighboring Ser594 as well as Arg551. In a parallel with
the thigh, connecting loops of the upper region of calf-1
also extend from b-strands composing a b-barrel; but here
it is mostly the main body of the constitutive amino acids
that engage in H-bonds. This gives a tighter structure, less
sensitive to amino acid substitutions, and with a greater
potential importance for steric impact. Arg755Pro or
Arg755Gln are well-studied examples of calf-1 missense
substitutions (Table S1). Although substitution of aII-
bArg755 by a Pro, an amino acid with a tendency to form
a b turn may directly introduce destabilization, the fact that
it points to the exterior of the b-barrel makes this less
likely. Immediately prior to submission of our manuscript,
Goguet et al. (2017) published in silico analysis of variants
within the calf-1 domain using a dynamic approach. While
confirming that the rigid nature of the calf-1 backbone
restricted short-range conformational change for substitu-
tions of Arg755 they additionally showed how long inde-
pendent molecular dynamic simulations revealed distant
allosteric changes that may contribute to the pathogenicity
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of calf-1 substitutions and show that short-range and long-
range changes both contribute to pathogenicity in GT.
The disease-causing effect of aIIbGln626His has a dif-
ferent explanation. Located immediately behind the genu, it
is the cause of type I GT in several unrelated families in
Europe with a c.1878G>C transversion affecting splicing
with loss of exon 28 resulting in truncated mRNA under-
going rapid decay (Jallu et al., 2010; Nurden et al., 2015).
The fact that expression of one natural and four engineered
aIIbGln626 variants with b3 in CHO cells had little effect
on integrin surface density (Jallu et al., 2010; Kamata
et al., 2010) led us to perform in silico modeling. Although
Gln626Asn and Gln626Asp have opposing charge effects
the substituted amino acids retain their ability to form H-
bonds with their counterpart Asn722 while that between
Asp495 and Ser759 is also retained, findings that may
explain the absence of a notable effect on expression after
mutagenesis. Even in the case of substitution of Gln626
with the smaller Ala and specific loss of the H-bond with
Asn722, no impact on integrin expression or its activation
state was reported (Kamata et al., 2010). Even more
intriguingly, introduction of the bulky Trp that disrupts the
H-bond not only with Asn722 but which pushes out the
nearby H-bond between aIIbAsp495 and Ser759 failed to
prevent integrin expression. Therefore in each case suffi-
cient structural integrity was retained to over-ride the qual-
ity control systems of the CHO cells during integrin
maturation. Interestingly, studies by Kamata et al. (2010)
also showed the recombinant integrins to be retained in a
non-activated (bent) form, except when substitution by Asn
created a N-glycosylation site, the bulky N-glycan now
being sufficient to cause swing-out of the hybrid domain,
integrin extension, and partial activation.
A striking feature of the a-subunit genu is a short,
disulfide-bonded loop first identified between residues 746
and 752 in aL and corresponding to residues 633 and 639
in aIIb (see Figure 1b) and a Ca2+-binding site that is
reportedly occupied in both the bent and extended forms
(Xie et al., 2004; Zhu et al., 2008). Coordination to genu
Ca2+ in aIIb is provided by the backbone carbonyl of
Cys633 and Val638, the side-chain of Asp636 and the
side-chain of Glu673 in calf-1 (Zhu et al., 2008). Knowl-
edge of this region was advanced by measuring binding of
two activation-dependent antibodies before and after activa-
tion of aLb2 (LFA-1) (Xie et al., 2004). In the bent con-
formation the aL-subunit calf domain and the nearby I-
EGF domains in the b leg shield key innermost thigh resi-
dues for antibody binding that become exposed on exten-
sion. On activation, the aL genu locks into an extended,
rigid, conformation with Ca2+ also favoring antibody bind-
ing (Xie et al., 2004). The structural rearrangement at the
genu was concluded to occur between the thigh domain
and the genu rather than between the genu and the calf-1
domain as the Ca2+-coordinating residue in calf-1 is main-
tained in the extended conformation. Within the bent av
conformation the Ca2+-coordinating residue Glu636 (corre-
sponding to aL calf-1 residue Glu787) is at the center of a
H-bonding network linking the genu to the calf-1 domain.
Thus av Glu636 coordinates both the Ca2+ and the genu
residue 603 backbone with its side chain and also forms
the backbone-backbone H bond to residue 603. No such
interactions exist between the genu and the thigh. No dis-
ease-causing mutation of amino acids engaged in Ca2+
coordination in aIIb (Cys633, Asp636, Val638 and
Glu673) has as yet been identified. To determine whether
this region was protected from genetic variation we
researched various databases and highlighted three rare
variants: Cys633Ser (rs1126555), Asp636Asn
(rs749873100), and Glu673Lys (rs368974006) (Ensembl
database). Modeling of these residues showed that Cys633-
Ser and Glu673Lys indeed do have a deep structural
impact: the first by disrupting a disulfide bridge, and the
second by pushing away the Ca2+ atom by steric encum-
brance. The presence of these potentially damaging muta-
tions presumed to exist as very rare single alleles in a
control population is compatible with the fact that
heterozygotes for GT generally do not bleed (George et al.,
1990). It would also be consistent with a constantly chang-
ing ITGA2B and ITGB3 mutation repertoire in the general
population (Buitrago et al., 2015; Nurden & Pillois, 2017).
Fundamental to our understanding of the structural
effects of genetic variants affecting the aIIb genu is the
conformation of the integrin during early aIIbb3 biosynthe-
sis and much less is known here. Of the 16 disease-contri-
buting variants that form the basis of our study, all but two
give rise to type I GT consistent with a severe block in pla-
telet aIIbb3 expression; only Ala477Pro and Cys705Arg
give rise to type II disease and low amounts of aIIbb3 on
platelets. Crucially, it has been suggested that proaIIbb3
rapidly adopts a bent conformation during biogenesis
(Mitchell, Li, French, & Coller, 2006; Mitchell et al.,
2007). Evidence for this was obtained through the use of
monoclonal antibodies specific for conformational-depen-
dent epitopes on aIIb or b3. Pro-aIIb itself acquires a bent
conformation soon after synthesis possibly through the
interaction of the b-propeller with calnexin or another
membrane-bound chaperone (Mitchell et al., 2006). b3 then
adopts a bent conformation on binding to pro-aIIb also in
a chaperone-dependent process. Pro-aIIbb3 complex forma-
tion occurs in the ER of MKs or transfected heterologous
cells and following carbohydrate processing the complexes
are transported to the Golgi apparatus where maturation
including cleavage of pro-aIIb into heavy and light changes
occurs prior to passage of mature aIIbb3 to the membrane
systems of platelets. Early adaptation of the bent conforma-
tion during aIIbb3 biosynthesis is highly compatible with
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the fact that pro-aIIbb3 formation was seen when aIIb477-
Pro and aIIb705Arg were expressed in b3-containing
heterologous cells (Fu et al., 2005; Gonzalez-Manchon
et al., 1999). However, the mechanisms by which the struc-
tural modifications of the thigh, genu and calf-1 as we have
observed for missense mutations by in silico modeling
cause the block in aIIbb3 maturation will require further
study. Among the hypotheses that can be put forward is a
reduced ability to bind chaperones necessary for pro-aIIbb3
transport from the ER to the Golgi apparatus. Not least, the
structural destabilization appears to cause retention of the
variant integrin in the ER with subsequent degradation by
the megakaryocyte proteosome. While our results validate
the use of in silico modeling as a rapid and inexpensive
way of confirming the probable pathogenicity of GT-caus-
ing missense mutations, they also urge caution in using this
approach alone, with additional long-range molecular
dynamic simulations and site-directed mutagenesis neces-
sary for a complete armamentarium.
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